Foghorn Therapeutics Inc

FHTX remains in a prolonged Stage 4 decline under sustained lower highs and lower lows with EMAs sloping downward and acting as resistance. The active Bearish Exhaustion pattern signals sellers losing control and increases the probability of a bottoming attempt or reversal bounce. Despite extreme oversold readings, lack of sustained reversal suggests selling is best deferred. Favor trimming on rallies into declining EMA regions or prior support-turned-resistance zones for structurally aligned execution.

• ↑Q2 collaboration revenue rose to $16.1M from $7.6M last year.
• ↑Net loss shrank to $7.2M from $17.9M as R&D expenses fell to $18.5M.
• ↓Profitability remains weak, failing to convert revenue into profit.